Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6

被引:38
作者
Hayhurst, GP [1 ]
Harlow, J [1 ]
Chowdry, J [1 ]
Gross, E [1 ]
Hilton, E [1 ]
Lennard, MS [1 ]
Tucker, GT [1 ]
Ellis, SW [1 ]
机构
[1] Univ Sheffield, Div Clin Sci, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
关键词
active site; homology models; ligand binding; N-dealkylation; site-directed mutagenesis;
D O I
10.1042/0264-6021:3550373
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Homology models of the active site of cytochrome P450 2D6 (CYP2D6) have identified phenylalanine 481 (Phe(481)) as a putative ligand-binding residue, its aromatic side chain being potentially capable of participating in pi-pi interactions with the benzene ring of ligands. We have tested this hypothesis by replacing Phe(481) with tyrosine (Phe(481) --> Tyr), a conservative substitution, and with leucine (Phe(481), Leu) or glycine (Phe(481) --> Gly), two non-aromatic residues, and have compared the properties of the wild-type and mutant enzymes in microsomes prepared from yeast cells expressing the appropriate cDNA-derived protein. The Phe(481) --> Tyr substitution did not alter the kinetics [K-m (muM) and V-max (pmol/min per pmol) respectively] of oxidation of S-metoprolol (27; 4.60), debrisoquine (46; 2.46) or dextromethorphan (2; 8.43) relative to the respective wild-type values [S-metoprolol (26; 3.48), debrisoquine (51; 3.20) and dextromethorphan (2: 8.16)]. The binding capacities K-s (muM)] of a range of CYP2D6 ligands to the Phe(481) --> Tyr enzyme (S-metoprolol, 22.8; debrisoquine, 12.5; dextromethorphan, 2.3; quinidine, 0.13) were also similar to those for the wild-type enzyme (S-metoprolol, 10.9; debrisoquine, 8.9; dextromethorphan, 3.1; quinidine, 0.10). In contrast, the Phe(481) --> Leu and Phe(481) --> Gly substitutions increased significantly (3-16-fold) the K-m, values of oxidation of the three substrates [S-metoprolol (12-124 muM), debrisoquine (152-184 muM) and dextromethorphan (20-31 muM)]. Similarly, the K-s values of the ligands to Phe(481) --> Leu and Phe(481) --> Gly mutants were also increased 3 to 10-fold (S-metoprolol, 33.2-41.9 muM; debrisoquine, 85-90 muM; dextromethorphan, 15.7-18.8 muM; quinidine 0.35-0.53 muM). However, contrary to a recent proposal that Phe(481) has the dominant role in the binding of substrates that undergo CYP2D6-mediated N-dealkylation routes of metabolism, the Phe(481) --> Gly substitution did not substantially decrease the capacity of the enzyme to N-deisopropylate metoprolol (wild-type, 1.12 pmol/min per pmol of P450; Phe(481) --> Gly, 0.71), whereas an Asp(301) --> Gly substitution decreased the N-dealkylation reaction by 95% of the wild-type rate. Overall. our results are consistent with the proposal that Phe(481) is a ligand-binding residue in the active site of CYP2D6 and that the residue interacts with ligands via a pi-pi interaction between its phenyl ring and the aromatic moiety of the ligand. However, the relative importance of Phe(481) in binding is ligand-dependent; furthermore, its importance is secondary to that of Asp(301). Finally, contrary to predictions of a recent homology model, Phe(481) does not seem to have a primary role in CYP2D6-mediated N-dealkylation.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 38 条
[1]  
[Anonymous], METHOD ENZYMOL
[2]   SIMULTANEOUS DETERMINATION OF DEXTROMETHORPHAN AND 3 METABOLITES IN PLASMA AND URINE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH APPLICATION TO THEIR DISPOSITION IN MAN [J].
CHEN, ZR ;
SOMOGYI, AA ;
BOCHNER, F .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :97-104
[3]   STRUCTURE OF CYTOCHROME P450ERYF INVOLVED IN ERYTHROMYCIN BIOSYNTHESIS [J].
CUPPVICKERY, JR ;
POULOS, TL .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (02) :144-153
[4]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[5]   A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6 [J].
de Groot, MJ ;
Ackland, MJ ;
Horne, VA ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (20) :4062-4070
[6]   Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6 [J].
de Groot, MJ ;
Ackland, MJ ;
Horne, VA ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (09) :1515-1524
[7]   Modeling the active sites of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes [J].
DeGroot, MJ ;
Vermeulen, NPE .
DRUG METABOLISM REVIEWS, 1997, 29 (03) :747-799
[8]   A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, p450 102, and P450 108 [J].
deGroot, MJ ;
Vermeulen, NPE ;
Kramer, JD ;
vanAcker, FAA ;
denKelder, GMDO .
CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (07) :1079-1091
[9]  
Ekins S, 1999, PHARMACOGENETICS, V9, P477
[10]   EVIDENCE THAT ASPARTIC-ACID-301 IS A CRITICAL SUBSTRATE-CONTACT RESIDUE IN THE ACTIVE-SITE OF CYTOCHROME-P450 2D6 [J].
ELLIS, SW ;
HAYHURST, GP ;
SMITH, G ;
LIGHTFOOT, T ;
WONG, MMS ;
SIMULA, AP ;
ACKLAND, MJ ;
STERNBERG, MJE ;
LENNARD, MS ;
TUCKER, GT ;
WOLF, CR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (49) :29055-29058